Raltegravir and etravirine are active against HIV type 1 group O

AIDS Res Hum Retroviruses. 2009 Feb;25(2):225-7. doi: 10.1089/aid.2008.0222.

Abstract

Abstract The activity of raltegravir and etravirine was assessed in vitro in HIV-1 group O isolates. Despite the presence of some natural polymorphisms associated with resistance to raltegravir (V72I, L74I, S153A, V201I, and T206S) and etravirine (G190A), both drugs showed significant antiviral activity. Subsequently, the clinical benefit was shown in an HIV-1 group O-infected individual in whom enfuvirtide was replaced by raltegravir. Therefore, individuals infected with HIV-1 group O might benefit from raltegravir and/or etravirine therapy.

Publication types

  • Case Reports

MeSH terms

  • Amino Acid Substitution / genetics
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use
  • Drug Resistance, Viral
  • Female
  • HIV Infections / virology*
  • HIV-1 / drug effects*
  • Humans
  • Middle Aged
  • Mutation, Missense
  • Nitriles
  • Pyridazines / pharmacology*
  • Pyridazines / therapeutic use
  • Pyrimidines
  • Pyrrolidinones / pharmacology*
  • Pyrrolidinones / therapeutic use
  • RNA, Viral / blood
  • Raltegravir Potassium
  • Viral Load

Substances

  • Anti-HIV Agents
  • Nitriles
  • Pyridazines
  • Pyrimidines
  • Pyrrolidinones
  • RNA, Viral
  • etravirine
  • Raltegravir Potassium